SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla shares rallied as investors positioned themselves ahead of the company's invite-only Cybercab launch event in Austin, leading to intense debate over whether the stock is primed for a 'buy the rumor, sell the news' pullback or further gains driven by the autonomous vehicle strategy.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing heavy selling pressure following disappointing second-quarter results and a significant downward revision to full-year guidance, with traders expressing concerns over slowing demand and increased competition. The community is sharply divided between those viewing the price drop as an overreaction and potential buying opportunity and those who believe the brand has lost its market relevance and pricing power.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing high volatility as traders react to a mixed earnings report that featured a revenue beat and raised guidance alongside investor concerns regarding slowing growth and AI adoption. While some community members view the dip as a strategic buying opportunity driven by institutional manipulation, others remain skeptical, citing valuation worries and a lack of clear momentum in agentic AI products.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is experiencing high volatility as traders react to a strong quarterly earnings beat and raised full-year guidance, though some investors remain concerned about slowing high-value customer growth and conservative fiscal outlooks. Market sentiment is polarized, with some investors viewing the stock as undervalued and a prime acquisition candidate while others express frustration over recent price underperformance relative to cybersecurity peers.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following a "double beat" in its fiscal second-quarter report, where the company exceeded analyst estimates for both revenue and earnings. While the immediate catalyst was the strong financial performance, sentiment is mixed as traders weigh the positive results against a softer-than-expected third-quarter revenue guidance, which management attributed to contract timing.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

The discussion remains fragmented as traders debate the impact of the company's upsized share repurchase program, with bulls viewing it as a sign of management's confidence and undervaluation, while bears argue it masks ongoing financial and governance concerns. Sentiment is mixed, characterized by persistent debate over the stock's long-term potential versus concerns regarding its OTC status and historical volatility.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending following positive fiscal second-quarter earnings that topped consensus estimates for EPS and revenue, alongside an increased annual recurring revenue outlook driven by its Intelligent Agreement Management (IAM) platform. While some traders view the results as a catalyst for a sustained recovery, others remain skeptical, citing concerns about competition from free alternatives and questioning if the stock's valuation is sustainable.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara shares are trending following a third-quarter earnings report that beat analyst expectations for both revenue and profit, driven by strong large-customer adoption and growth in its connected operations platform. While the results prompted several analysts to raise their price targets, traders are debating the company's long-term growth trajectory and the sustainability of its valuation.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victoria's Secret shares experienced a sharp decline following second-quarter results that fell slightly short of Wall Street's revenue expectations, despite a profit beat and an updated full-year outlook. Traders are currently divided between viewing the selloff as an oversold buying opportunity and fearing further downside due to concerns over weak sequential growth.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors react to a proposed 500 million share offering, which has sparked significant community debate regarding dilution and the company's capital needs. Despite bearish sentiment surrounding the financing news, many traders remain focused on the potential November PDUFA date for their cancer drug, ivonescimab, and view recent price weakness as an accumulation opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Equity

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.


Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average   - Here's What Happened

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-lexicon-pharmaceuticals-inc-stock...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High  - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - What's Next...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High  - Should You Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Still a Buy...

• Reported GAAP EPS of -$0.07 down -800.00% YoY
• Reported revenue of $0.69M down -97.60% YoY

Lexicon Pharmaceuticals experienced a significant revenue decline and a shift to net loss in the second quarter of 2026, while navigating ongoing clinical development and complex regulatory approval requirements.

Lexicon Pharmaceuticals achieved key clinical enrollment milestones for its Phase 3 SONATA-HCM study and continues to advance ZYNQUISTA regulatory resubmission efforts alongside strategic development partnerships for its late-stage pipeline candidates.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Bullish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$2.26
Prev Close	$2.24
Open	$2.25
Dividend Yield	0.00%
50-Day Moving Average	$2.33
Beta	1.60
Avg. Volume	2.96M
PE Ratio	-14.76

52-Week High	$2.68
52-Week Low	$1.05
Market Capitalization	$996.7M
EPS (Annual)	-$0.1387
Price to Book	5.76
Revenue Per Employee	$614,851.85

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXRX Fundamentals